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The effects of guanine nucleotides on arachidonic acid (AA) release were studied in intact and saponin-permeabilized 
human platelets. While GTP[S] itself caused a stimulation of AA release in permeabilized cells, GTP[S], GDP[St, GTP, 
ATP and other nucleotides inhibited AA release in response to thrombin and other agonists in intact, as well as permeabil- 
ized platelets. Inhibition of agonist-stimulated AA release by nucleotides was partially attenuated by addition of ADP, 
and was abolished by prior stimulation of platelets to discharge the ADP-containing dense granules. These results suggest: 
(i) that released ADP plays an important contributory role in agonist-stimulated platelet AA release, and (ii) that guanine 
nucleotides can modulate platelet activation through an extracellular action which is distinct from their effects on 
G-proteins. 
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1. INTRODUCTION 
A number of investigators have recently pro- 
vided evidence that AA release may be under the 
control of one or more guanine nucleotide-binding 
regulatory proteins (G-proteins) in human 
platelets. The evidence can be summarized as 
follows: the G-protein activators fluoroaluminate 
and GTP[S] stimulate AA release when added to 
platelets [l-4], and the G-protein inhibitors 
GDP[S] and pertussis toxin inhibit AA release in 
response to the physiological agonist thrombin [4]. 
During studies using permeabilized human 
platelets, we observed that thrombin-stimulated 
AA release is profoundly inhibited not only by 
GDP[S], but surprisingly also by GTP[S], GTP, 
Correspondence address: S.P. Halenda, Department of Phar- 
macology, University of Missouri School of Medicine, Colum- 
bia, MO 65212, USA 
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phosphate plus creatine phosphokinase; FAF-BSA, fatty acid- 
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(2-thiodiphosphate); GppNHp, guanylylimidodiphosphate; 
GTP[S], guanosine- ‘-0-(3-thiotriphosphate) 
GDP, ATP and many other nucleotides. The pre- 
sent study was undertaken to determine the 
mechanism by which exogenous nucleotides can in- 
hibit agonist-induced platelet responses. 
2. EXPERIMENTAL 
Human platelet suspensions were prelabeled with [‘H]AA as 
previously described [5] and gel-filtered through Sepharose 2B 
columns equilibrated with a modified Tyrode-Hepes medium 
composed of 134 mM NaCl, 2.9 mM KCI, 4 mM NaHC03, 
0.36 mM NaHzPOd, 1 mM MgClz, 5 mM dextrose, 0.2 mg/ml 
FAF-BSA and 10 mM Hepes. All incubation media, including 
those which contained added nucleotides, were adjusted to pH 
7.40 at 37°C. The final platelet density was l-2 x lO’/ml. 
Platelet samples (0.5 ml) were preincubated with nucleotides 
and/or the ADP scavenger CP/CPK for 5 min prior to addition 
of thrombin or other agonists; incubations were then ter- 
minated after an additional 5 min. For experiments utilizing 
degranulated platelets, a procedure similar to that reported by 
Kinlough-Rathbone et al. [6] was followed. Washed platelets 
(109/ml) were suspended in medium containing 1 mM EGTA 
and no added divalent cations. Platelets were then treated either 
with 1 pM A23187 for 5 min, or with 1 U/ml thrombin for 
2 min at 23°C followed by addition of 2 U/min hirudin and 
10 nM prostacyclin. Control experiments revealed that these 
conditions resulted in maximal @O-90%) discharge of dense 
granule contents, as assessed by measuring the release of 
[‘Hlserotonin from prelabeled platelets. Degranulated platelets 
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were then washed, labeled with [3H]AA, and gel-filtered as 
described above. For studies with saponin-permeabilized 
platelets, [‘H]AA-prelabeled cells were gel-filtered into a 
medium composed of 135 mM NaCl, 5 mM KCl, 1 mM MgClz, 
1 mM dextrose, 0.5 mg/ml FAF-BSA and 20 mM Hepes. In- 
cubations were begun by diluting 50 pl of concentrated (l-2 x 
lo9 cells/ml) platelet suspension into 450 ~1 of a medium com- 
posed of 140 mM KCl, 1 mM MgClz, 1 mM dextrose, 
0.5 mg/ml FAF-BSA, 20 mM Hepes, 12gg/ml saponin and 
any desired pretreatments. Following a 5 min period to allow 
complete permeabilization of platelets, stimuli were added and 
incubations were terminated after an additional 5 min. Release 
of [‘H]AA and metabolites into the medium was assayed as 
described previously [5]. All data shown are representative of at 
least four separate platelet preparations which gave closely 
similar results. 
Nucleotides were purchased from Boehringer Mannheim or 
Sigma, trypsin (TPCK-treated) was from Sigma. All other 
materials were from sources described previously [5,7]. 
3. RESULTS AND DISCUSSION 
As shown in fig. 1, the addition of G-protein ac- 
tivator GTP[S] to saponin-permeabilized platelets 
elicited a modest stimulation of [3H]AA release. 
The stimulatory effect of GTP[S] was not seen in 
nonpermeabilized cells. Surprisingly, the G- 
protein inhibitor GDP[S] also caused a slight, but 
consistent stimulation of [3H]AA release, whereas 
GTP was without effect. We predicted that if the 
platelet agonist thrombin activates AA release 
through a thrombin receptor/G-protein interac- 
tion, then GTP or GTP[S] might potentiate the ac- 
tion of submaximal concentrations of thrombin in 
permeabilized cells. However, all three guanine 
nucleotides substantially inhibited thrombin- 
stimulated [3H]AA release at thrombin concentra- 
tions above 0.5 U/ml, and no potentiation was evi- 
dent at lower concentrations (fig. 1). Nucleotides 
had no apparent effect of their own on intact 
(nonpermeabilized) platelets up to the highest con- 
centration tested, 3 mM (not shown). 
[3H]AA release stimulated by thrombin and 
other platelet agonists (trypsin, collagen) in intact 
cells was also inhibited by guanine nucleotides, 
ATP and other nucleotides as shown in table 1. 
Half-maximal inhibition of the response to 1 U/ml 
thrombin was attained at 306 f 74 ,uM ATP 
(mean + SE from 5 experiments) and the thrombin 
response was 85-95% inhibited at 3 mM ATP. 
Nucleosides, phosphate and pyrophosphate 
(1 mM) were not inhibitory (not shown). The fact 
I I 
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Fig. 1. Effects of guanine nucleotides on thrombin-stimulated 
[3H]AA release in saponin-permeabilized platelets. Nucleotide 
concentrations were: CiTP[S], 10 pM; GDP[S], 100 PM; GTP, 
1 mM. Experimental conditions are described in section 2. Data 
are means from duplicate determinations which varied by less 
than 4%. 
that nucleotides, which are highly charged, 
hydrophilic compounds, can inhibit responses in 
intact cells implies that their site of action is ex- 
tracellular. Platelets are known to possess cell sur- 
face receptors for the weak platelet agonist ADP, 
and ATP is a competitive antagonist at this unique 
purine receptor (review [8]). Upon stimulation, 
platelets release ADP and other substances tored 
in dense granules, thus providing a feedback 
stimulatory pathway which may amplify the effect 
of the primary stimulus. Although platelet activa- 
tion by the strong agonist thrombin is generally 
thought to be largely independent of the actions of 
released ADP, the present findings raise the 
possibility that released ADP plays a significant 
role in the stimulation of [3H]AA mobilization by 
thrombin, and that nucleotides may inhibit the 
thrombin response through blockade of the ADP 
receptor. 
To explore this possibility we tested the follow- 
ing three criteria. First, if nucleotides inhibit 
thrombin-stimulated [3H]AA release by blocking 
the action of released ADP, then the enzymatic 
removal of released ADP should inhibit the throm- 
bin response in a manner similar to nucleotides. 
Fig.2 shows that the ADP scavenger CP/CPK in- 
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Table 1 20 
Inhibitory effect of nucleotides on agonist-stimulated AA 
release 
Agonist Nucleotide AA release % inhibition 
(cpm) 
None none 532 + 12 _ 
Thrombin (1 U/ml) none 11924 rt 296 _ 
GTP 6456 + 65 48 
GTP[S] 5024 + 443 61 
GPPNHP 8468 t 176 30 
GDP 7208 k 293 41 
GDP[S] 4959 + 255 61 
GMP 11939 + 155 0 
ATP 3570 f 90 13 
UTP 5361 z+ 123 58 
CTP 4199 + 31 68 
Trypsin (10 pg/ml) none 10752 +- 611 _ 
ATP 3387 * 316 72 
GTP 5784 & 114 49 
GDP[S] 5423 & 78 52 
Collagen (40 fig/ml) none 7827 + 577 - 
ATP 2465 + 392 74 
All nucleotides were present at 1 mM. Data are means + range 
from duplicate determinations 
Fig.2. Inhibition of thrombin-stimulated [3H]AA release by the 
ADP scavenger system, creatine phosphate (5 mM) plus 
creature phosphokinase (10 U/ml). [ATP] was 1 mM. Data are 
means * range (indicated by the bars unless smaller than the 
symbols) from duplicate determinations. 
hibits thrombin-stimulated [3H]AA release, 
especially at low thrombin concentrations. The in- 
hibitory nucleotide ATP caused little or no addi- 
tional inhibition when added in the presence of 
CP/CPK, consistent with the belief that both in- 
hibitors share a common mechanism of action, i.e. 
interference with released ADP. Similar inhibition 
was seen with apyrase as an ADP scavenger, and 
with trypsin as the platelet stimulus (not shown). 
centrations (0.01-0.1 U/ml) at which secretion of 
dense granule contents was found to be submax- 
imal, we consistently observed an enhancement of 
thrombin-stimulated [3H]AA release by l-10 PM 
20 
Second, if the nucleotides are acting as com- 
petitive inhibitors at the ADP receptor, then the in- 
hibitory effects of nucleotides should be overcome 
by addition of exogenous ADP. As shown in fig.3, 
added ADP attenuated (by approx. 50%) the in- 
hibition of thrombin-stimulated [3H]AA release 
caused by GDP[S]. Similar attenuation was seen 
for ATP, GTP, GTP[S] and other inhibitory 
nucleotides (not shown). For these experiments, 
conditions were chosen such that ADP itself would 
have little effect of its own on [3H]AA release. 
Thus, our washed platelet suspensions did not con- 
tain fibrinogen which is required for direct platelet 
responses to this weak agonist [9]. Also, ADP had 
little effect on the response to 1 U/ml thrombin 
alone (fig.3). However, with lower thrombin con- 
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Fig.3. Attenuation by ADP of the inhibitory effect of GDP[S] 
on thrombin-stimulated [3H]AA release. Drug concentrations 
were: thrombin, 1 U/ml; GDP[S], 1 mM; ADP, 100~M. 
Increasing [ADP] to 1 mM did not result in a greater reversal 
of inhibition (not shown). Data are means (+ SD) from 
triplicate determinations. 
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ADP under the same experimental conditions (not 
shown). 
And third, in degranulated platelets in which 
agonist-induced discharge of ADP can no longer 
occur, nucleotides should not be able to inhibit 
other agonist-induced responses if they are acting 
simply as ADP antagonists. Fig.4 depicts a typical 
experiment in which platelets were degranulated by 
prior stimulation with the Ca2+ ionophore A23 187, 
labeled with [3H]AA and then challenged with 
thrombin. In striking contrast to nondegranulated 
cells in which nucleotides and CP/CPK were in- 
hibitory (figs 1-3, table l), a complete loss of in- 
hibition or even a potentiation of thrombin- 
stimulated [3H]AA release by nucleotides and 
CP/CPK was seen in degranulated platelets (fig.4). 
Note in fig.4 that ADP enhanced the stimulatory 
effect of 1 U/ml thrombin in degranulated 
platelets as opposed to nondegranulated platelets 
(fig.3), further supporting a role for released ADP 
in the thrombin response. In some experiments, 
platelets were degranulated by thrombin pretreat- 
ment. Fig.5 shows that in this preparation, 
GDP[S] and ATP no longer inhibit trypsin- 
stimulated [3H]AA release in either intact or 
saponin-permeabilized cells. 
Taken together, these results suggest that the in- 
hibitory effect of GDP[S] and other nucleotides on 
agonist-stimulated AA release is exerted, at least in 
Fig.4. Thrombin (1 U/ml)-stimulated [3H]AA release in 
A23187-degranulated platelets. See section 2 for experimental 
details. [ADP] was 10pM; concentrations of other 
pretreatments are given in the legends for table 1 and fig.2. 
Data are means (f SD) from triplicate determinations. 
Intact Permeabilized 
Fig.5. Trypsin (10 pg/ml)-stimulated [3H]AA release in 
thrombin-degranulated platelets. Nucleotide concentrations 
were 1 mM. Data are means (rt SD) from triplicate samples. 
part, through a competitive blockade of the 
platelet surface ADP receptor. Nucleotide-induced 
inhibition was not restricted to AA release as the 
agonist response, but was seen also for thrombin- 
or trypsin-stimulated serotonin secretion and 
[3H]arachidonyl diacylglycerol formation (not 
shown). Following the completion of this study, a 
paper by Krishnamurthi et al. [lo] appeared which 
reported an inhibition of agonist-stimulated ag- 
gregation, serotonin secretion, Ca2+ mobilization 
and protein phosphorylation by guanine 
nucleotides in human platelets. It is therefore clear 
that the entire range of platelet responses can be 
suppressed by exogenous nucleotides, including 
GDP[S], at concentrations which are commonly 
used for experiments in permeabilized cells. Thus, 
it is doubtful that GDP[S] can be of value as a 
selective G-protein inhibitor in human platelets. 
Furthermore, these studies provide direct evidence 
for the importance of released ADP as a con- 
tributing factor in platelet activation. 
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